Novavax Inc. said Tuesday its experimental coronavirus vaccine induced promising immune responses and was generally well-tolerated in healthy adults in the first human study of the shot. Two weeks after taking a second dose, most vaccinated subjects had high levels of so-called neutralizing antibodies.
Trending:
Novavax COVID-19 vaccine produces positive results in first-stage study